- Home
- JMIA vs TNGX Comparison
JMIA vs TNGX Comparison
Compare JMIA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMIA
- TNGX
- Stock Information
- Founded
- JMIA 2012
- TNGX 2014
- Country
- JMIA Germany
- TNGX United States
- Employees
- JMIA N/A
- TNGX N/A
- Industry
- JMIA Catalog/Specialty Distribution
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- JMIA Consumer Discretionary
- TNGX Health Care
- Exchange
- JMIA Nasdaq
- TNGX Nasdaq
- Market Cap
- JMIA 406.6M
- TNGX 351.2M
- IPO Year
- JMIA 2019
- TNGX N/A
- Fundamental
- Price
- JMIA $3.46
- TNGX $5.36
- Analyst Decision
- JMIA Buy
- TNGX Strong Buy
- Analyst Count
- JMIA 2
- TNGX 6
- Target Price
- JMIA $7.88
- TNGX $12.20
- AVG Volume (30 Days)
- JMIA 2.7M
- TNGX 3.9M
- Earning Date
- JMIA 08-05-2025
- TNGX 08-06-2025
- Dividend Yield
- JMIA N/A
- TNGX N/A
- EPS Growth
- JMIA N/A
- TNGX N/A
- EPS
- JMIA N/A
- TNGX N/A
- Revenue
- JMIA $154,854,000.00
- TNGX $40,990,000.00
- Revenue This Year
- JMIA $10.62
- TNGX N/A
- Revenue Next Year
- JMIA $7.08
- TNGX N/A
- P/E Ratio
- JMIA N/A
- TNGX N/A
- Revenue Growth
- JMIA N/A
- TNGX 10.09
- 52 Week Low
- JMIA $1.60
- TNGX $1.03
- 52 Week High
- JMIA $15.04
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- JMIA 59.14
- TNGX 81.35
- Support Level
- JMIA $3.10
- TNGX $4.70
- Resistance Level
- JMIA $3.27
- TNGX $5.37
- Average True Range (ATR)
- JMIA 0.21
- TNGX 0.58
- MACD
- JMIA -0.02
- TNGX 0.07
- Stochastic Oscillator
- JMIA 66.92
- TNGX 89.89
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.